Multiple myeloma treated with high dose intravenous melphalan
Multiple myeloma treated with high dose intravenous melphalan
复制标题
高剂量静脉注射马法兰治疗多发性骨髓瘤
DOI：
10.1111/j.1365-2141.1987.00045.x-i1
复制
发表时间：
1987
影响因子：
6.5
通讯作者：
J. Malpas
中科院分区：
文献类型：
--
作者：
P. Selby;T. Mcelwain;A. Nandi;T. Perren;R. Powles;C. Tillyer;R. Osborne;M. Slevin;J. Malpas
高剂量melphalan （HDM， 140mg /m2静脉注射）治疗58例63岁以下多发性骨髓瘤患者。在先前未接受治疗的患者中，11/41（27%）进入完全缓解（CR：没有可测量的骨髓瘤蛋白和正常骨髓），21（51%）进入部分缓解（骨髓瘤蛋白减少50%以上，所有其他特征改善）。中位缓解期为19个月。2例对既往常规治疗有反应的患者在HDM后进入CR。在15例既往化疗失败的患者中，反应率为66%，包括2例复发。然而，本组患者均在1年内复发。所有患者均出现严重骨髓抑制、中度恶心、呕吐、黏膜炎和腹泻并可逆性脱发。治疗2个月内有10例死亡，主要原因是败血症和出血。
High dose melphalan (HDM, 140 mg/m2 i.v.) has been evaluated in 58 patients under 63 years with multiple myeloma. Among previously untreated patients 11/41 (27%) entered a complete remission (CR: no measurable myeloma protein and a normal bone marrow) and 21 (51%) entered a partial remission (more than 50% reduction in myeloma protein and improvement in all other features). Median duration of remission is 19 months. Two patients who had responded to previous conventional treatment entered CR after HDM. Among 15 patients who had failed on previous chemotherapy the response rate was 66% including two CRs. However, in this group all patients have relapsed within 1 year. Profound myelosuppression, moderate nausea, vomiting, mucositis and diarrhoea with reversible alopecia occurred in all patients. There were 10 deaths within 2 months of treatment mainly due to sepsis and haemorrhage.
影响因子：
158.5
作者：
BARLOGIE, B;SMITH, L;ALEXANIAN, R
通讯作者：
ALEXANIAN, R
高剂量马法兰联合自体骨髓移植治疗多发性骨髓瘤。
影响因子：
20.3
作者：
Barlogie,B;Hall,R;Zander,A;Dicke,K;Alexanian,R
通讯作者：
Alexanian,R